Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Deffered Revenue (2016 - 2017)

Abeona Therapeutics (ABEO) has 7 years of Non-Current Deffered Revenue data on record, last reported at $3.1 million in Q4 2017.

  • For Q4 2017, Non-Current Deffered Revenue fell 16.46% year-over-year to $3.1 million; the TTM value through Dec 2017 reached $3.1 million, down 16.46%, while the annual FY2017 figure was $3.1 million, 16.46% down from the prior year.
  • Non-Current Deffered Revenue reached $3.1 million in Q4 2017 per ABEO's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $5.5 million in Q2 2013 and bottomed at $2.6 million in Q1 2013.
  • Average Non-Current Deffered Revenue over 5 years is $4.3 million, with a median of $4.3 million recorded in 2015.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 101.21% in 2014, then decreased 16.46% in 2017.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $5.2 million in 2013, then decreased by 7.12% to $4.9 million in 2014, then decreased by 12.37% to $4.3 million in 2015, then decreased by 14.11% to $3.7 million in 2016, then fell by 16.46% to $3.1 million in 2017.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $3.1 million in Q4 2017, $3.2 million in Q3 2017, and $3.4 million in Q2 2017.